Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 31 March 2026

Swixx BioPharma
CHF
311
million
(Fair value CHF 310.6 million / 15.7% of total assets)
more
CHF
170
million
Cathay Biotech
(Fair value CHF 170.0 million / 8.6% of total assets)
more
Neurelis
CHF
67
million
(Fair value CHF 66.5 million / 3.4% of net assets)
more
Argenx
CHF
58
million
(Fair value 57.9 million / 2.9% of total assets)
more
CHF
51
million
Zymeworks
(Fair value CHF 50.5 million / 2.5 of net assets)
more
CHF
48
million
Harmony Biosciences
(Fair value 48.1 million / 2.4% of total assets)
more
ArriVent BioPharma
CHF
47
million
(Fair value CHF 47.0 million / 2.4% of total assets)
more
CHF
39
million
Swixx Healthcare
(Fair value CHF 38.7 million / 2.0% of total assets)
more
Alumis Therapeutics
CHF
28
million
(Fair value 27.8 million / 1.4% of total assets)
more
Abivax
CHF
27
million
(Fair value CHF 26.7 million / 1.3% of total assets)
more